Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 16daratumumab 9Bortezomib 9Lenalidomide 6pomalidomide 4carfilzomib 4isatuximab 3trametinib 2selinexor 2dabrafenib 2Thalidomide 2Prednisone 2Melphalan 2ulixertinib 1trastuzumab biosimilar HLX02 1talquetamab 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1montelukast 1melflufen 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1darlin protein, Dictyostelium 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Multiple Myeloma × darlin protein, Dictyostelium × Clear all
NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡